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Abstract
Background: Sleep problems are common, affecting over a third of adults in the United Kingdom
and leading to reduced productivity and impaired health-related quality of life. Many of those whose
lives are affected seek medical help from primary care. Drug treatment is ineffective long term.
Psychological methods for managing sleep problems, including cognitive behavioural therapy for
insomnia (CBTi) have been shown to be effective and cost effective but have not been widely
implemented or evaluated in a general practice setting where they are most likely to be needed and
most appropriately delivered. This paper outlines the protocol for a pilot study designed to
evaluate the effectiveness and cost-effectiveness of an educational intervention for general
practitioners, primary care nurses and other members of the primary care team to deliver problem
focused therapy to adult patients presenting with sleep problems due to lifestyle causes, pain or
mild to moderate depression or anxiety.
Methods and design: This will be a pilot cluster randomised controlled trial of a complex
intervention. General practices will be randomised to an educational intervention for problem
focused therapy which includes a consultation approach comprising careful assessment (using
assessment of secondary causes, sleep diaries and severity) and use of modified CBTi for insomnia
in the consultation compared with usual care (general advice on sleep hygiene and
pharmacotherapy with hypnotic drugs). Clinicians randomised to the intervention will receive an
educational intervention (2 × 2 hours) to implement a complex intervention of problem focused
therapy. Clinicians randomised to the control group will receive reinforcement of usual care with
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sleep hygiene advice. Outcomes will be assessed via self-completion questionnaires and telephone
interviews of patients and staff as well as clinical records for interventions and prescribing.
Discussion: Previous studies in adults have shown that psychological treatments for insomnia
administered by specialist nurses to groups of patients can be effective within a primary care setting.
This will be a pilot study to determine whether an educational intervention aimed at primary care
teams to deliver problem focused therapy for insomnia can improve sleep management and
outcomes for individual adult patients presenting to general practice. The study will also test
procedures and collect information in preparation for a larger definitive cluster-randomised trial.
The study is funded by The Health Foundation.
Trial Registration: ClinicalTrials.gov ID ISRCTN55001433 – http://www.controlled-trials.com/
ISRCTN55001433
Background
Insomnia and sleep problems are common, affecting over
a third of adults in the United Kingdom.[1,2] Many of
those whose lives are affected seek medical help from pri-
mary care.[3] A review of cost effectiveness studies of diag-
nosis and treatment of insomnia highlighted that
insomnia has a high economic cost on society, particu-
larly in terms of productivity loss and impaired health-
related quality of life.[4]
General practitioners and nurse prescribers have been
shown to have a limited repertoire of responses (sleep
advice sheet, prescription) when managing new patients
or reviewing those with insomnia. Clinical responses are
shaped by unduly positive attitudes towards newer hyp-
notics[5] and limited by lack of knowledge of alternative
non-pharmacological approaches. This leads to manage-
ment strategies that often involve the prescription of hyp-
notic drugs, despite the finding that GPs hold less than
favourable views of these drugs overall.[6] Evidence also
suggests that hypnotic prescribing fosters patient depend-
ency and passive 'help seeking behaviour' involving fur-
ther requests for prescriptions. The clinical benefits of
hypnotics are small and short-lived. They also carry signif-
icant risks of adverse events, for example increases in risk
of falls, fractures,[7] depression[8], suicide[9] and excess
mortality.[10] These dangers are particularly pronounced
in the elderly who are most vulnerable to potential
harm.[11] A compelling case exists for both improving
quality of care for these patients and doing so by encour-
aging changes in prescribing, although there is less evi-
dence about how to achieve these outcomes.
We could find no published evidence on the costs of poor
sleep in the UK. However in the US the costs (direct, indi-
rect and related) of insomnia have been estimated at
US$30 to 35 billion per annum (1994 US$) [12] and in
Australia AUS$7494 million (2004 AUS$) of which 53%
was accounted for by work-related injuries (net of health
costs), private motor vehicle accidents (net of health
costs) and productivity losses associated with sleep disor-
ders.[13] The review by Martin et al.[4] made three
research recommendations encompassing the need for
more accurate costs for patients with different types of
insomnia related diagnosis, an estimate of the health util-
ities associated with particular insomnia diagnoses and
their treatments and finally to undertake cost utility anal-
yses of treatments for insomnia to encourage resource
allocation to this area.
We have shown in modelling studies involving patients,
practitioners and practices that despite patients trying var-
ious self-help remedies and sometimes expecting a pre-
scription when presenting with sleep problems, they also
welcome a consultation approach which includes careful
assessment and advice about non-pharmacological meth-
ods rather than a prescription. [14-16] Practitioners are
generally positive towards finding new approaches that
enhance their skills in non-pharmacological management
methods. Brief psychological/behavioural methods[17]
have also been shown to be effective in one previous lim-
ited evaluation of effectiveness.[18]
The objective of this paper is to describe the design of a
pilot cluster randomised controlled study, the aim of
which is to test procedures and collect information in
preparation for a larger definitive cluster-randomised
trial. The definitive study will determine the effectiveness
and cost-effectiveness of an educational intervention for
general practitioners, primary care nurses and other mem-
bers of the primary care team to deliver problem focused
therapy to adults patients presenting with sleep distur-
bance due to primary insomnia or specific comorbid
insomnia due to pain or mild to moderate depression and
anxiety compared to usual care (general advice on sleep
hygiene and pharmacotherapy).
The team includes a general practitioner, psychologist,
psychiatrist, qualitative researcher, statistician and health
economist and a service user representative who haveBMC Family Practice 2009, 10:9 http://www.biomedcentral.com/1471-2296/10/9
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worked together undertaking studies of sleep manage-
ment in primary care and have contributed to the ration-
ale and design of this study.
Methods
Aims
Our main aim for the pilot study is to test procedures and
collect information in preparation for a larger definitive
cluster-randomised trial. The definitive trial will investi-
gate the effectiveness and cost-effectiveness of a brief prac-
tice-based educational intervention (2 × 2 hours) for
practice teams (GPs, primary care nurses and practice
managers) to provide problem focused therapy for insom-
nia in adults involving the use of sleep assessment tools
(assessed with standardised instruments and sleep dia-
ries) and modified CBTi on sleep outcomes compared to
usual care (general advice on sleep hygiene and pharma-
cotherapy). The study will include new patients present-
ing with primary and specific comorbid insomnia as well
as patients with chronic insomnia on treatment.
The research question for the pilot trial is "How well do
the procedures and processes designed for conduct of the
trial lead to effective implementation of trial including
recruitment, randomisation, intervention, and outcome
measurements."
The research question for the main trial is as follows "How
effective and cost-effective is an educational intervention
to primary care teams (general practitioners, primary care
nurses and practice managers) to deliver problem focused
therapy to adult patients presenting with sleep problems
due to lifestyle causes, pain or mild to moderate depres-
sion on sleep and quality of life compared with treatment
as usual including sleep hygiene and pharmacotherapy?"
The primary hypothesis for the main trial to be addressed
is:
"Education for primary care teams in problem focused
therapy for patients presenting to primary care with
insomnia leads to better sleep outcomes for patients com-
pared to treatment as usual with sleep hygiene up to 3
months from the beginning of treatment."
Secondary hypotheses for the main trial include: "Educa-
tion for primary care teams in problem focused therapy
for patients presenting to primary care with insomnia
improves daytime sleepiness, anxiety and depression,
health-related quality of life and reduces hypnotic use,
adverse effects and costs compared to treatment as usual
including sleep hygiene."
Study design
This study will be a pilot in preparation for a larger cluster-
randomised trial. The purpose of undertaking this pilot
will include testing the integrity of study protocol, recruit-
ment and consent issues, outcome selection, data collec-
tion procedures, the randomisation procedure, and the
acceptability of the intervention and determining a more
accurate sample size.
A flow diagram summarizing recruitment and follow-up
of physicians and patients is shown in Figure 1. We will
undertake a pilot cluster randomised controlled trial
(RCT) in which general practices are the unit of randomi-
sation and where data will be collected from patients.
Recruited general medical practices will be randomised to
one of two arms: intervention consisting of education of
primary care teams to use Problem Focused Therapy for
insomnia comprising sleep assessment tools (sleep diaries
and Insomnia Severity Index) and modified CBTi
(mCBTi); or a control arm using treatment as usual (TAU).
We will follow the CONSORT statement extension on
conduct and reporting of cluster randomised controlled
trials.[19]
Participants
The Practices
We will recruit four practices from Lincolnshire Teaching
Primary Care Trust using EMIS or SystemOne computer
systems. Each practice will need to recruit at least 20
patients, based on the sample size calculation for a defin-
itive RCT who meet the inclusion criteria in order to
achieve the estimated sample size of 80 patients. Practices
will be randomised to intervention and control groups
once the practices have been recruited but allocation will
be concealed until after patients have been recruited in
order to reduce bias in selection and recruitment of
patients to intervention and control practice.[20] Invita-
tion letters will be sent out to all practices in Northwest
Lincolnshire (40 practices) inviting participation. Patients
will be recruited from practices that agree to participate.
Study population
Intervention and controls patients will include adults
aged 18 years and over with primary or specific secondary
(comorbid) insomnia having a Pittsburgh Sleep Quality
Index (PSQI) of 5 or above and screened by a trial nurse
for the following inclusion and exclusion criteria[21].
Inclusion criteria
1. At least 18 years old.
2. Difficulty initiating and/or maintaining sleep for 1
month or more verified by PSQI score of ≥5.
3. New presentations with insomnia and existing patients
on long term hypnotics, over the counter or complemen-
tary therapies.
4. 1–3 above and sleep disrupted by painful conditions.BMC Family Practice 2009, 10:9 http://www.biomedcentral.com/1471-2296/10/9
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Consort diagram Figure 1
Consort diagram.BMC Family Practice 2009, 10:9 http://www.biomedcentral.com/1471-2296/10/9
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5. 1–3 above and depression measured by the Beck
Depression Inventory (BDI score 11–30).
Exclusion criteria
1. Current or previous illicit substance or alcohol abuse.
2. Pregnant or planning pregnancy in the next 12 months
3. Psychotic illness and severe depression defined by a
BDI score ≥ 31.
4. Documented or active symptoms of sleep disruptive
comorbid conditions e.g. restless legs syndrome and any
type of parasomnia.
5. Obstructive sleep apnoea.
6. Terminal Illness.
7. Inability to consent.
8. Current participation in another research study.
Participant recruitment
Eligible patients will be recruited by the GP, practice nurse
or self referred (via a poster in the GP waiting room). After
reading an information leaflet potential participants will
register their interest to take part in the trial using a tear-
off slip (see Figure 2).
At least 48 hours after and within 10 working days of reg-
istering their interest, patients will be telephoned by the
trial nurse (this is a practice based nurse trained to recruit
and consent patients) to explain the study and check
whether they still wish to participate. If the patient is inter-
ested the trial nurse will assess the patient against the
above listed inclusion and exclusion criteria. Information
will be recorded on a standard proforma including, for
patients either not eligible or not willing to be recruited,
the reason for ineligibility or for declining. Patients meet-
ing the criteria will be sent an invitation by post to an ini-
tial assessment visit together with a copy of the Patient
Information Sheet (PIS), consent form and baseline
demographic questionnaire.
When the patient attends for the initial assessment a
(practice based) trial nurse will discuss the PIS with the
patient and gain informed consent. The PSQI and BDI will
be carried out and checked against the inclusion and
exclusion criteria requirements.
If the patient is fully eligible and informed consent is
obtained the participant will be entered into the trial. The
trial nurse will register the patient with the Trial Centre via
a Safehaven fax system. The patient will be allocated a
unique trial number by the trial centre. The trial nurse will
inform the patient's GP that they have been entered into
the trial. The rest of the baseline assessments will be per-
formed at this stage (EuroQol EQ-5D, ESS, ISI, Sleep
Diary, and PSYCHLOPS). An appointment will be made
for the GP or practice nurse to begin assessment/treatment
within 10 working days of the practice being allocated to
either the intervention or control group or in the interven-
tion practices, after training of the practice teams on prob-
lem focused therapy for insomnia.
Recruitment is planned to take place over 3 months using
the methods described above including posters in GP
waiting rooms and reminders to GPs and nurses sup-
ported by an information leaflet. During the recruitment
phase patients will continue to receive treatment as usual.
Randomisation and allocation concealment
Participating practices will be numbered and randomised
to two groups using a computer-generated list of practice
identifiers and these will be passed on to the statistician
(who will be an investigator remote from the study site)
blind to the identity of the practices and using random
numbers to ensure allocation concealment. The list will
be returned to trial staff, who will break the code and
identify the practice allocation when patient recruitment
is complete. This information will not be returned to the
statistician (MD) so that he will remain masked to treat-
ment allocation while undertaking the analysis. Because
of the nature of the study it will not be possible to mask
the practices or patients to the intervention but we shall
take all possible steps to conduct the analysis masked to
treatment.
Intervention general practices
The intervention will consist of two two-hour educational
sessions, using a previously published model of academic
detailing to primary care teams.[22] GPs, practice nurses
and practice manager will be invited to participate. The
importance of all members of the team, including practice
managers being involved is due to the key need, demon-
strated in the modelling studies, for management support
in developing the pathway of care within practices. The
first session will include the background to the study, trial
structure and procedures, assessment of sleep problems
including the use of sleep assessment tools and measure-
ments and information on sleep hygiene. The second ses-
sion will be on the use of problem focused therapy in the
consultation which includes careful assessment (using
assessment of secondary causes, sleep diaries and severity)
and modified cognitive behavioural therapy for insom-
nia. This session will also involve practice teams designing
their own pathway for care. The timing and number of
educational sessions is based on previous modelling stud-
ies with a group of 8 practices.BMC Family Practice 2009, 10:9 http://www.biomedcentral.com/1471-2296/10/9
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Participant recruitment flowchart Figure 2
Participant recruitment flowchart.BMC Family Practice 2009, 10:9 http://www.biomedcentral.com/1471-2296/10/9
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Control general practices
The control practices will also receive the first session of
training which will include the background to the study,
trial structure and procedures, assessment of sleep prob-
lems including the use of sleep assessment tools and
measurements and information on sleep hygiene. They
will continue their usual practice (treatment as usual) sup-
ported by a standard sleep hygiene leaflet. In the UK, treat-
ment as usual consists of advice on sleep hygiene (with or
without a patient information leaflet) and hypnotic phar-
macotherapy. We will provide advice on sleep hygiene
and a sleep hygiene leaflet for control practices. Sleep
hygiene consists of a good bedtime routine, avoiding alco-
hol, caffeine and nicotine and ensuring a comfortable
sleeping environment.
Audit of interventions and activity
Primary care teams in the intervention practices will be
required to send all clinicians and the practice manager to
the educational sessions. Further educational sessions will
be provided to clinical staff newly recruited during the
study period as the need arises. GPs and nurses in inter-
vention and control practices will record patients who
present with insomnia and their use of sleep assessment
and problem focused therapy techniques using practice
computer systems. The content and usefulness of training
will be assessed using questionnaires to those in receipt of
training. Intervention and control practices will be
audited on implementation of the educational interven-
tion by measuring use of assessment and CBTi techniques
used by undertaking a weekly computer Read codes audit
of all patients recorded with insomnia as well as asking
patients through telephone interviews. A sample of up to
4 patients and practitioners from each practice will be
invited for a short telephone interview (20 minutes) to
understand in more depth the interventions that have
been delivered and received as well as perceptions
towards these. The interview will determine fidelity to the
intervention in study practices and contamination in the
control practices and therefore will not be blinded.
Outcomes
The primary outcome measure will be global sleep quality
as measured by PSQI at baseline and at 0, 4, 8 and 13
weeks.
Secondary outcomes will be measured at baseline and at
0,4,8 and 13 weeks and will include the effect of the inter-
vention on sleep outcome measures assessed with PSQI
and sleep diaries [23]: self reported Sleep Onset Latency
(SOL, how long it takes to fall asleep), Wake time After
Sleep Onset (WASO, total hours awake at night after one
has fallen asleep), total Time In bed (TIB) and Sleep Effi-
ciency (SE). Sleep Efficiency, expressed as a percentage, is
calculated as follows: SE = (100-[(SOL + WASO/TIB) ×
100]). Research has shown that these subjective measures
of sleep reflect subjective treatment-related improve-
ments.
We will also measure daytime sleepiness (Epworth sleep-
iness scale),[24] anxiety and depression using the Beck
Depression Inventory,[25] health-related quality of life
using EuroQol EQ-5D,[26] psychological outcome profile
(PSYCHLOPS)[27] and frequency of use and mean dose
of hypnotic medication. Patients will also keep a Data
Record Book (DRB) to record any adverse effects that they
might experience during the treatment period. Cost-effec-
tiveness will be assessed using the methods below.
Follow-up
Primary and secondary outcomes will be measured using
the instruments described at baseline and 0, 4, 8 and 13
weeks. Follow-up assessments will be performed using a
telephone call at 2 weeks after the first treatment and self-
completed postal questionnaires at all other time points.
Non responders will be telephoned 1 week after mailing
the follow-up questionnaire on up to 2 occasions and
posted a replacement questionnaire with a reminder letter
if there is still no response at 2 weeks.
Criteria and procedure for withdrawal of patients from the 
trial
A patient may be withdrawn or themselves withdraw from
the trial at any time, at his/her own discretion or at that of
the GP or researcher if there is any suspicion of adverse
effects or an exclusion condition (including loss of capac-
ity to consent) supervening. The reasons for interrupting
the patient's participation in the trial will be recorded on
the summary page of the Data Record Book (DRB) and
the patient ' proforma. His/her GP will be notified of the
need for clinical follow up.
Justification of sample size
Assuming an intracluster correlation coefficient (ICC) of
0.01 we need at least 15 practices per arm and a cluster
size of 20 (i.e. 20 patients in each practice) giving 300
patients per arm to detect a difference of 1 point in the
PSQI with 90% power for a definitive RCT. This would
require a major investment of resources and therefore we
will first conduct an exploratory trial to understand the
feasibility of a full trial. For our exploratory trial we will
take a pragmatic decision to include 4 practices, 2 inter-
vention and 2 control practices.
Methods of data collection
Patient level data will be collected from patients using
self-report questionnaires, and researchers by telephone.
Outcomes will be measured at baseline and at week 0, at
4 weeks, and at 8 and 13 weeks from the initial treatment
whether treatment has been completed or not (i.e. on an
intention to treat basis).BMC Family Practice 2009, 10:9 http://www.biomedcentral.com/1471-2296/10/9
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Data analysis
Data collection and statistical analysis will be undertaken
on both clustered data and on individual patient data
masked to treatment allocation and on an intention to
treat basis. Data will be analysed at baseline, at 0, 4, 8 and
13 weeks. Baseline clinical and demographic data will be
analysed for important differences between trial groups.
Comparisons between treatment arms before and after
intervention will be made using proportions and odds
ratios. We shall analyse the primary outcome using linear
regression with baseline as a covariate and also control-
ling for other relevant baseline covariates. We shall ana-
lyse our primary outcome, the PSQI, at the level of the
patient using a multivariable model which adjusts for
baseline PSQI and for the clustering due to practices. We
shall carry out similar analyses for our secondary out-
comes. In addition we shall extend our model to incorpo-
rate all the time points. This will be a mixed effects model
with random effects for time and practice. This model has
the advantage that sporadic missing data can be coped
with if it is missing at random (MAR). If there is substan-
tial dropout we shall examine it using a pattern mixture
model which does not have the restriction to MAR. We
shall conduct analogous analyses for the other secondary
outcomes. Statistical significance will be set at 5% (two
tailed) and analysis performed using Stata or other statis-
tical software. No interim analysis of the primary or sec-
ondary outcomes will be undertaken during the trial
period.
Template analysis will be used to undertake a qualitative
analysis of a short telephone interview (20 minutes) to
investigate perceptions of practitioners and patients on
interventions delivered and received in each practice with
4 patients and 4 practitioners from each intervention and
control practice.
Health economic analysis
Since a cost analysis will be undertaken for the main trial
and the instruments and methods will be piloted in this
study, the rationale and methods are therefore described
below. Given the high cost of insomnia and the need for
economic research in this area, the economic evaluation
for the main study will estimate the cost-utility of a brief
educational intervention for primary care teams (GPs,
nurses and practice managers) to improve sleep manage-
ment using problem focused therapy (including CBTi)
compared to usual care provided by GPs and nurses from
a health and social care perspective in the base case. The
wider costs will be captured separately. Established and
accepted economic methodologies will be employed
throughout.[28,29]
Resource items likely to change as a result of the interven-
tion (as well as the cost of developing and providing the
educational intervention) will be identified, measured
and valued drawing upon instruments used in other stud-
ies and available from published resources.[30] The base
case will capture only those costs incurred by the NHS and
social care (including, for instance, patient visits to health
and social care professionals, outpatient visits and admis-
sions to secondary care, and medication) using patient
level data extracted from self completion questionnaires
administered at baseline, 0, 8 and 13 weeks. This will
include all health and social care resource use (due to the
difficulties of disentangling) which are consumed as a
result of sleep problems per se rather than because of
other causes. Where feasible the wider costs associated
with sleep problems will be monitored through patient
questionnaires, in particular we will attempt to estimate
patient costs, particularly associated with health care
usage (for instance, over the counter medication and
travel costs) and the productivity costs (both absenteeism
and presenteeism) [31,32] of patients, whether due
directly to sleep problems or accidents, to see if the inter-
vention has any impact on the patient's wider well-being.
Unit costs will be derived from national published data
(for instance, NHS reference costs,.[33] Annual Survey of
Hours and Earnings (ASHE)) for the most recent price
year available or local unit costs will be estimated where
appropriate and feasible.
This study will undertake cost-effectiveness and cost util-
ity analyses. Both types of analyses enable technical effi-
ciency questions to be addressed, that is to ask, is an
educational intervention for health professionals a cost
effective way in which to improve the management of
patients with sleep problems? In addition, cost-utility
analysis will also enable allocative efficiency questions to
be addressed within the health sector, for instance, is the
brief educational intervention about CBTi considered in
this study cost-effective compared to a diverse range of
other health interventions or services? This study will esti-
mate the cost-effectiveness in terms of cost per 1 point
change on the Pittsburgh Sleep Quality Index (PSQI) and
the cost utility using the EuroQol EQ-5D http://
www.euroqol.org[26] to estimate the cost per QALY over
the trial period. Both outcome instruments will be admin-
istered at baseline and 13 weeks to observe if change
occurs as a result of the intervention and whether it is sus-
tained.
The timeframe for the economic analysis will be that of
the trial period. The change in costs will be divided by the
change in effectiveness in order to estimate the cost effec-
tiveness of the brief educational intervention compared to
no brief educational intervention for health professionals.
If non-dominance occurs (that is if costs are greater and
the intervention is more effective or if the intervention is
cheaper and less effective) an incremental cost-effective-BMC Family Practice 2009, 10:9 http://www.biomedcentral.com/1471-2296/10/9
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ness ratio (the ratio of change in cost divided by change in
benefit) will be produced. The confidence region around
the incremental cost effectiveness ratio will be estimated
using appropriate statistical techniques. Since this eco-
nomic evaluation is being undertaken alongside a cluster
randomised trial the analysis needs to reflect the increased
uncertainty of randomising clusters rather than individu-
als, a number of approaches have recently been proposed
each found to generate similar findings.[34] The stochas-
tic analysis will enable a cost effectiveness acceptability
curve to be produced [35] illustrating the decision uncer-
tainty, that is the probability that the brief educational
intervention for health professionals on improving sleep
management is cost-effective compared to no educational
intervention/usual care for a range of willingness to pay
per QALY values.
Ethical approval
The study has been approved by the National Research
Ethics Service (REC reference number: 08/H0401/89) and
NHS Lincolnshire (Trent) Research Governance. All data
will be stored confidentially in encrypted files. Practices
will give informed written consent and individual patient
consent will also be needed. Data will be kept securely for
13 years.
Discussion and conclusion
The objective of this study is to test the procedures for a
definite trial investigating the effectiveness and cost-effec-
tiveness of an educational intervention for general practi-
tioners, primary care nurses and other members of the
primary care team to deliver problem focused therapy to
adult patients presenting with sleep problems and anxiety
compared with usual care (general advice on sleep
hygiene and/or sleeping tablets). Problem focused ther-
apy includes a consultation approach comprising careful
assessment (using assessment of secondary causes, sleep
diaries and severity) and the use of modified CBTi for
insomnia.
This trial is designed to test procedures and collect data in
preparation for a larger definitive cluster-randomised trial
which will investigate the effectiveness and cost-effective-
ness of a brief practice-based educational intervention (2
× 2 hours) for practice teams (GPs, primary care nurses
and practice managers) to provide problem focused ther-
apy for adults presenting with sleep problems in primary
care due to lifestyle causes, pain or mild to moderate
depression. It will include new patients presenting with
primary and specific comorbid insomnia as well as
patients with chronic insomnia on treatment.
The intervention was developed using the theoretical and
modelling phases of the Medical Research Council Frame-
work for complex interventions.[36,37] We are conduct-
ing this trial in a primary care population using a team
based educational intervention which has been used pre-
viously.[22]
This trial will form the basis of a definitive cluster trial of
a carefully modelled psychological intervention for
patients presenting with sleep problems to be managed in
a primary care setting. If problem focused therapy is effec-
tive and safe when delivered by primary care clinicians
this will have a potential impact for sufferers who are
often inappropriately prescribed drugs long term with evi-
dence of more harm than benefit in the elderly. The study
would have the potential of providing evidence to
improve management of insomnia for a large number of
sufferers and thereby to improve the well-being, mental
and physical health of many people with sleep problems.
If a definitive trial shows that such an intervention is effec-
tive and cost-effective this would provide valuable infor-
mation to general practitioners, mental health trusts and
commissioners for provision of such services. If the treat-
ment is shown to be ineffective or costly then this will also
provide valuable information about whether such treat-
ment should be provided.
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